title: Role of transarterial chemoembolization for hepatocellular carcinoma before liver transplantation with special consideration of tumor necrosis.
abstract: Several authors suggest that local ablative therapies, specifically transarterial chemoembolization (TACE), may control tumor progression of hepatocellular carcinoma (HCC) in patients who are on the waiting list for liver transplantation (orthotopic liver transplantation, OLT). There is still no evidence if TACE followed by OLT is able to prevent recurrence of tumor, to prolong survival rate of the patients on the waiting list, or to improve the survival after OLT. We report 27 patients with HCC who underwent OLT. From these patients, 15 were pre-treated with TACE alone or in combination with percutaneous ethanol injection (PEI) or laser-induced thermo therapy (LITT). Mean time on the waiting list was 214 d for treated patients and 133 d for untreated patients. Comparing pre-operative imaging and histopathological staging post-transplant, we found 13 patients with tumor progression out of which five were treated with TACE. In two of the TACE patients a decrease of lesions could be achieved. In a single patient, there was no evidence of any residual tumor. Only one patient displayed tumor progression prior to OLT despite undergoing TACE. Comparison of outcome in patients undergoing TACE or having no TACE was not statistically significant (p = 0.5). In addition, our analysis showed that progression either in the total study population or in the TACE group alone is associated with a significant poorer outcome concerning overall survival (p = 0.02 and p = 0.02).
authors.affiliation: Department of General and Vascular Surgery, University of Frankfurt, Frankfurt, Germany.
authors.forename: André
authors.initials: A
authors.lastname: Schaudt
authors.forename: Susanne
authors.initials: S
authors.lastname: Kriener
authors.forename: Wolfram
authors.initials: W
authors.lastname: Schwarz
authors.forename: Christoph
authors.initials: C
authors.lastname: Wullstein
authors.forename: Stephan
authors.initials: S
authors.lastname: Zangos
authors.forename: Thomas
authors.initials: T
authors.lastname: Vogl
authors.forename: Arianeb
authors.initials: A
authors.lastname: Mehrabi
authors.forename: Hamidreza
authors.initials: H
authors.lastname: Fonouni
authors.forename: Wolf O
authors.initials: WO
authors.lastname: Bechstein
authors.forename: Markus
authors.initials: M
authors.lastname: Golling
mesh_terms: D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000601:surgery / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000601:surgery / Q000628:therapy*; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016019:Survival Analysis; D014850:Waiting Lists; D055815:Young Adult